2
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

5-Fluorouracil and Recombinant Alpha Interferon-2a in the Treatment of Advanced Colorectal Carcinoma: a Dose Optimization Study

, &
Pages 327-330 | Published online: 14 Jul 2016

References

  • Sugarbaker PH, McDonald JS, Gunderson LL. Colorectal cancer. In De Vita VT, Hellmann S, Rosenberg SA eds. Principles and Practice of Oncology. Philadelphia JP Lippincott Co., 1982: 686–710.
  • Petrelli N, Herrera L, Rustum Y et al. A prospective randomized trial of 5FU versus 5FU and high dose leucovorin versus 5FU and MTX in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol, 1987; 5: 1559–1565.
  • Doroshow JH, Bertrand M, Multhauf P. Prospective randomized trial comparing 5FU versus 5FU and high dose folinic acid for treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol, 1987; 6: 96.
  • Erlichman C, Fine S, Wong A et al. A randomized trial of 5-fIuorouracil and leucovorin in patients with metastatic colorectal carcinoma. J Clin Oncol, 1988; 6: 469–472.
  • Valone FH, Drakes T, Flam M et al. Treatment of patients with advanced colorectal carcinoma with fluorouracil alone, high dose leucovorin plus 5-fluorouracil or sequential methotrexate, fluorouracil and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol, 1989; 1427–14326.
  • Di Costanzo F, Bartolucci R, Sofra M et al. 5-Fluorouracile vs alte dosi di acido folinico e 5-fluorouracile nel carcinoma del colon-retto avanzato. Studio randomizzato del Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). In Di Costanzo F, ed. L’associazione fluorouracile e folati, Terni, March 30–31, 1990: 71–85.
  • Sobrero A, Nobile MT, Vidili Mg et al. Randomized trial of the maximum tolerated dose of weekly bolus 5-fluorouracil alone or combined with high-dose leucovorin in advanced measurable colorectal cancer. In Pinedo HM & Rustum YM eds, Leucovorin Modulation of Fluoropyrimidines: New Frontiers Cancer Chemotherapy, Royal Society of Medicine Service, 1989: 47–51.
  • Wadler S, Lyver A, Goldmann M et al. Therapy with 5-fluorouracil (5FU) and recombinant alpha 2a — interferon (IFN) in refractory GI malignancies. Proc Am Soc Clin Oncol, 1989; 8: 99.
  • Wadler S, Schwartz E, Goldman M et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol, 1989; 7: 1769–1775.
  • Wadler S, Wiernik P. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Sem Oncol, 1990; 17, suppl. 1: 16–21.
  • Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol, 1984; 2: 336–352.
  • Neefe JR, Silgals R, Ayoob M et al. Minimal activity of recombinant clone A interferon in metastatic colon cancer. J Biol Resp Mod, 1984; 3: 366–370.
  • Brouth-Body D, Towey MG. Inhibition by interferon of thymidine uptake in chemostat cultures of L1210 cells. Intervirology, 1978; 9: 243–252.
  • Gewert DR, Shah S, Clemens MJ. Inhibition of cell division by interferons: changes in the transport and intracellular metabolism of thydimine in human lvmphoblastoid (Daudi) cells. Eur J Biochem, 1981; 116: 487–492.
  • Elias J, Crissman HA. Interferon effects upon the adenocarcinoma 38 and HL60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res, 1988; 48: 4868–4873.
  • Barone C, Astone A, Cassano A et al. Interferon, folati e 5-fluorouracile nel cancro del colon in fase avanzata. In Di Costanzo F ed, L’associazione fluorouracile e folati, Terni, March 30–31, 1990: 153–161.
  • Stolfi RL, Martin DS, Sawyer RC et al. Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with interferon inducer, polyinosinic acid. Cancer Res, 1983; 43: 561–566.
  • Wadler S, Goldmann M, Lyver A et al. Phase I trial of 5-fluorouracil and recombinant alpha-2a-interferon in patients with advanced colorectal carcinoma. Cancer Res, 1990; 50: 2056–2059.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.